Low Volatility Stocks For Uncertain Fed Signals and Rising Market Swings

With Kevin Warsh stepping in as Fed chair and pulling back on forward guidance, markets have been reminded how uncomfortable uncertainty can feel. Stock prices fell and bond yields rose after his first meeting, which pushed many investors to rethink their appetite for sharp swings. That is where a focus on low volatility stocks comes in. This article looks at 3 stocks from a Low Volatility Stocks screener that appear more closely tied to this news event. The goal is to help you judge whether these steadier profiles fit your own risk comfort as the Fed’s playbook becomes less transparent.

LivaNova (LIVN)

Overview: LivaNova is a UK headquartered medical technology company that sells cardiopulmonary equipment such as heart lung machines and oxygenators, along with neuromodulation devices that use vagus nerve stimulation to help treat drug resistant epilepsy, depression and obstructive sleep apnea.

Operations: LivaNova generates most of its revenue from Cardiopulmonary at about US$817.7m and Neuromodulation at about US$605.7m, with smaller contributions from other activities.

Market Cap: US$4.53b

LivaNova stands out in a more volatile Fed backdrop because its cardiopulmonary and neuromodulation products serve ongoing medical needs rather than discretionary demand. This can support a steadier revenue profile as some investors look for lower volatility ideas. Analysts highlight revenue and earnings growth expectations that are supported by stronger data in obstructive sleep apnea, a growing recurring revenue mix around high value equipment and services, and recent index additions that may broaden the shareholder base. At the same time, the company carries funding risk from higher reliance on external borrowing, faces reimbursement and regulatory pressure, and trades on a relatively rich P/E. The key consideration is how these strengths and pressures balance out for a healthcare stock that may behave differently when markets react to shifts in Fed communication.

LivaNova’s recurring cardiopulmonary and neuromodulation revenue, richer P/E and external funding needs create a tricky mix. To see how that trade off really looks, review the DCF valuation analysis for LivaNova

Cooper Companies (COO)

Overview: Cooper Companies develops and sells contact lenses for common vision issues such as myopia, astigmatism and presbyopia through CooperVision, and provides a range of women’s and family health products and services, including fertility consumables, genetic testing and the Paragard intrauterine device, through CooperSurgical.

Operations: Cooper Companies generates most of its revenue from CooperVision at about US$2.85b and CooperSurgical at about US$1.38b.

Market Cap: US$14.48b

Cooper Companies may appeal to investors seeking steadier healthcare exposure at a time when the Fed’s less predictable stance is contributing to greater day‑to‑day market swings. The company is focusing on premium daily lenses such as MyDAY and specialty products like MiSight for myopia management, while also working to improve efficiency and free cash flow after a period of heavy investment. At the same time, recent results included a net loss, contact lens market growth has slowed, and fertility and IUD businesses are under pressure, so execution on product rollouts and pricing is an important consideration. For a more detailed view of these moving parts, including future earnings expectations and funding risks, the full story on Cooper Companies lays out the trade offs in a structured way.

Cooper Companies appears to present stalled earnings optics but potentially improving cash generation. Scan the analyst forecasts for Cooper Companies to see how premium lenses and women’s health could reshape the risk profile while one key issue still lingers.

AngioDynamics (ANGO)

Overview: AngioDynamics is a US based medical technology company that develops devices used by doctors to treat cardiovascular disease and certain cancers, including systems that remove blood clots, clear blocked vessels and ablate soft tissue in minimally invasive procedures.

Operations: AngioDynamics generates about US$150.0m from its Med Tech segment and about US$170.2m from Med Device, with most of its roughly US$320.2m in sales coming from the United States and a smaller portion from international markets.

Market Cap: US$627.0m

AngioDynamics may interest investors who want healthcare exposure that can be less tied to daily market swings and that still has room for changes in sentiment if its story develops favorably. The Med Tech portfolio, including Auryon and NanoKnife, targets procedures that treat chronic conditions. Index additions to Russell 2000 defensive indices show how the stock can screen as a steadier profile. At the same time, the company continues to report net losses, faces reimbursement and regulatory hurdles, and operates against larger competitors that can pressure pricing. The combination of a medical device business seeking a path to profitability and a sector that some investors view as relatively resilient when Fed signals are less clear is what many investors may want to examine more closely.

AngioDynamics is trying to shift from losses to a more resilient profile. Yet the real story sits in how its products and funding needs stack up against rivals. Walk through the analysis report for AngioDynamics

The three healthcare stocks here are just a starting point, as the full Low Volatility Stocks screener surfaced 14 more companies in Consumer Staples, Utilities and Healthcare with similarly detailed stories behind their risk, balance sheet strength and future outlook. To identify the highest conviction ideas for your own portfolio, use Simply Wall St to analyze and filter the specific catalysts and narratives in the Low Volatility Stocks screener via the Low Volatility Stocks screener.

Take Control of Your Investment Journey

If LivaNova or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd?

Fresh stock ideas can move from quiet to flying once momentum builds. Scan these curated shortlists before the crowd catches on and the ideal entry window starts dropping, and consider acting early.

• Consider targeting resilient compounding by reviewing a curated 7 dividend fortresses that aims to keep income flowing even when markets react sharply to new Fed signals.
• Explore structural energy trends by checking a focused set of 89 nuclear energy infrastructure stocks that could be relevant if demand for stable baseload power continues.
• Review the next hardware cycle by scanning carefully filtered 55 AI infrastructure stocks supporting the compute backbone behind today’s AI workloads.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com